|Ms. Julie M. Eastland M.B.A.||Pres, CEO & Director||339.67k||N/A||1964|
|Dr. Natalie R. Sacks M.D.||Consultant||751.79k||N/A||1965|
|Ms. Georgia L. Erbez||Consultant||628.26k||N/A||1967|
|Dr. Holger Wesche Ph.D.||Chief Scientific Officer||N/A||N/A||1968|
|Ms. Wendy Chang||Sr. VP of HR||N/A||N/A||N/A|
|Ms. Rachael Lester||Sr. VP of Bus. Devel. & Corp. Strategy||N/A||N/A||N/A|
|Dr. Banmeet Anand Ph.D.||Sr. VP of Translational Medicine||N/A||N/A||N/A|
|Dr. Luke N. Walker M.D.||Chief Medical Officer||N/A||N/A||1972|
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics, Inc.’s ISS Governance QualityScore as of November 28, 2022 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 8.